The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

282 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.EBI
Jadavpur University
Discovery of a new selective inhibitor of A Disintegrin And Metalloprotease 10 (ADAM-10) able to reduce the shedding of NKG2D ligands in Hodgkin's lymphoma cell models.EBI
San Raffaele Scientific Institute
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.EBI
Pfizer
Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.EBI
University Of Minnesota
N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity.EBI
Universit£
Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.EBI
Takeda Pharmaceutical
Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.EBI
Universidad Ceu San Pablo
Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1¿ binding site.EBI
Takeda Pharmaceutical
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.EBI
University Of Lille
Arylsulfonamide inhibitors of aggrecanases as potential therapeutic agents for osteoarthritis: synthesis and biological evaluation.EBI
Universit£
Synthesis and structure-activity relationship analysis of caffeic acid amides as selective matrix metalloproteinase inhibitors.EBI
Nanjing University Of Chinese Medicine
Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).EBI
Second Military Medical University
Sulphonamides: Deserving class as MMP inhibitors?EBI
Indian Institute Of Technology (Bhu)
Synthesis and preliminary evaluation in tumor bearing mice of new (18)F-labeled arylsulfone matrix metalloproteinase inhibitors as tracers for positron emission tomography.EBI
Universit£
Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.EBI
Pomona College
Design and synthesis of procollagen C-proteinase inhibitors.EBI
Fibrogen
Discovery of highly potent and selective small molecule ADAMTS-5 inhibitors that inhibit human cartilage degradation via encoded library technology (ELT).EBI
Glaxosmithkline
Remarkable potential of thea-aminophosphonate/phosphinate structural motif in medicinal chemistry.EBI
Wroclaw University Of Technology
A one-pot synthesis and biological activity of ageladine A and analogues.EBI
Macquarie University
Structure-Activity Relationship for Thiirane-Based Gelatinase Inhibitors.EBI
TBA
Natural products as a gold mine for selective matrix metalloproteinases inhibitors.EBI
East China University Of Science And Technology
Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis.EBI
Alantos Pharmaceuticals
Antidotes to anthrax lethal factor intoxication. Part 3: Evaluation of core structures and further modifications to the C2-side chain.EBI
Panthera Biopharma
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University Of Florida
Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety.EBI
Incyte
Current perspective of TACE inhibitors: a review.EBI
The M. S. University Of Baroda
1-Hydroxy-2-pyridinone-based MMP inhibitors: synthesis and biological evaluation for the treatment of ischemic stroke.EBI
Johnson & Johnson Pharmaceutical Research And Development
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).EBI
Johnson & Johnson Pharmaceutical Research And Development
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.EBI
Johnson & Johnson Pharmaceutical Research And Development
Carbamoylphosphonate matrix metalloproteinase inhibitors 6: cis-2-aminocyclohexylcarbamoylphosphonic acid, a novel orally active antimetastatic matrix metalloproteinase-2 selective inhibitor--synthesis and pharmacodynamic and pharmacokinetic analysis.EBI
The Hebrew University Of Jerusalem
Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
Alpha,beta-cyclic-beta-benzamido hydroxamic acids: novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Research And Development
Synthesis and evaluation of novel heterocyclic MMP inhibitors.EBI
North Dakota State University
Designed multiple ligands. An emerging drug discovery paradigm.EBI
Organon Laboratories
N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP.EBI
Universit£
Receptor flexibility in the in silico screening of reagents in the S1' pocket of human collagenase.EBI
De Novo Pharmaceuticals
Fragment-based drug discovery.EBI
Sunesis Pharmaceuticals
Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids.EBI
The Hebrew University Of Jerusalem
Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors.EBI
Institut De Recherches Servier
Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI
Wyeth Research
Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.EBI
Wyeth Research
New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.EBI
Nippon Organon K.K.
Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.EBI
Dupont Pharmaceuticals
Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases.EBI
TBA
Protease inhibitors: current status and future prospects.EBI
University Of Queensland
Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors.EBI
Parke-Davis Pharmaceutical Research
Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.EBI
F. Hoffmann-La Roche
Design, synthesis, and biological evaluation of potent thiazine- and thiazepine-based matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.EBI
Procter And Gamble Pharmaceuticals
Discovery of potent, achiral matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Phosphoramidate peptide inhibitors of human skin fibroblast collagenase.EBI
University Of Kentucky
Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.EBI
Pfizer
Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.EBI
Pfizer
Heterocycle-based MMP inhibitors with P2' substituents.EBI
Procter And Gamble Pharmaceuticals
The discovery of anthranilic acid-based MMP inhibitors. Part 3: incorporation of basic amines.EBI
Wyeth-Ayerst Research
alpha-Alkyl-alpha-amino-beta-sulphone hydroxamates as potent MMP inhibitors that spare MMP-1.EBI
Pfizer
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinases.EBI
Wyeth-Ayerst Research
The discovery of anthranilic acid-based MMP inhibitors. Part 1: SAR of the 3-position.EBI
Wyeth-Ayerst Research
The discovery of anthranilic acid-based MMP inhibitors. Part 2: SAR of the 5-position and P1(1) groups.EBI
Wyeth-Ayerst Research
Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.EBI
Celltech-Chiroscience
Synthesis and activity of selective MMP inhibitors with an aryl backbone.EBI
Pharmacia
Macrocyclic hydroxamate inhibitors of matrix metalloproteinases and TNF-alpha production.EBI
Dupont Pharmaceuticals
Synthesis of an array of potential matrix metalloproteinase inhibitors using a sequence of polymer-supported reagents.EBI
University Of Cambridge
Picking the S1, S1' and S2' pockets of matrix metalloproteinases. A niche for potent acyclic sulfonamide inhibitors.EBI
Universit£
The synthesis and biological activity of a novel series of diazepine MMP inhibitors.EBI
Wyeth-Ayerst Research
In silico scaffold evaluation and solid phase approach to identify new gelatinase inhibitors.EBI
Colosseum Combinatorial Chemistry Centre For Technology (C4T Scarl)
Potent inhibitors of LpxC for the treatment of Gram-negative infections.EBI
Pfizer
Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2.EBI
Astrazeneca
Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds.EBI
Scripps Florida
Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.EBI
Boehringer Ingelheim Pharmaceuticals
Novel 1-hydroxypiperazine-2,6-diones as new leads in the inhibition of metalloproteinases.EBI
Instituto Superior T£Cnico
Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors.EBI
Microbiotix
Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.EBI
Universit£
Discovery of novel Cobactin-T based matrix metalloproteinase inhibitors via a ring closing metathesis strategy.EBI
Johnson & Johnson Pharmaceutical Research & Development
Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.EBI
University Of Illinois At Chicago
Selective water-soluble gelatinase inhibitor prodrugs.EBI
University Of Notre Dame
Orally active MMP-1 sparinga-tetrahydropyranyl anda-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease.EBI
Pfizer
Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.EBI
Universit£
Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis.EBI
Astrazeneca
Structure and activity relationships of tartrate-based TACE inhibitors.EBI
Merck Research Laboratories
MMP-13 selectivea-sulfone hydroxamates: a survey of P1' heterocyclic amide isosteres.EBI
Pfizer
MMP-13 selective alpha-sulfone hydroxamates: identification of selective P1' amides.EBI
Pfizer
2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.EBI
Merck Research Laboratories
Discovery of (1S,2R,3R)-2,3-dimethyl-2-phenyl-1-sulfamidocyclopropanecarboxylates: novel and highly selective aggrecanase inhibitors.EBI
Central Pharmaceutical Research Institute
The design and synthesis of novel N-hydroxyformamide inhibitors of ADAM-TS4 for the treatment of osteoarthritis.EBI
Astrazeneca
Sulfonate-Containing Thiiranes as Selective Gelatinase InhibitorsEBI
TBA
Structure-based approach to nanomolar, water soluble matrix metalloproteinases inhibitors (MMPIs).EBI
Protera
Structure based optimization of chromen-based TNF-a converting enzyme (TACE) inhibitors on S1' pocket and their quantitative structure-activity relationship (QSAR) study.EBI
Yonsei University
Novel TNF-a converting enzyme (TACE) inhibitors as potential treatment for inflammatory diseases.EBI
Merck Research Laboratories
MMP-13 selective isonipecotamide alpha-sulfone hydroxamates.EBI
Pfizer
Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.EBI
Pfizer
Potent arylsulfonamide inhibitors of tumor necrosis factor-alpha converting enzyme able to reduce activated leukocyte cell adhesion molecule shedding in cancer cell models.EBI
Universit£
Discovery and SAR of hydantoin TACE inhibitors.EBI
Merck Research Laboratories
Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors.EBI
Central Pharmaceutical Research Institute
The discovery of novel tartrate-based TNF-alpha converting enzyme (TACE) inhibitors.EBI
Schering-Plough Research Institute
Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.EBI
Pfizer
The identification of beta-hydroxy carboxylic acids as selective MMP-12 inhibitors.EBI
Gsk Medicines Research Centre
Design, synthesis, biological evaluation, and NMR studies of a new series of arylsulfones as selective and potent matrix metalloproteinase-12 inhibitors.EBI
Universit£
Identification of an orally efficacious matrix metalloprotease 12 inhibitor for potential treatment of asthma.EBI
Wyeth Research
N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.EBI
Universit£
Discovery of novel hydroxamates as highly potent tumor necrosis factor-alpha converting enzyme inhibitors. Part II: optimization of the S3' pocket.EBI
Schering-Plough Research Institute
 
Inhibition of Matrix Metalloproteinases: An examination of the S1′ pocketEBI
TBA
 
Asymmetric synthesis of a conformationally constrained N-phosphonoalkyl dipeptideEBI
TBA
 
Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimicsEBI
TBA
 
Orally active inhibitors of stromelysin-1 (MMP-3)EBI
TBA
 
Inhibition of matrix metalloproteinases by P1 substituted N-carboxyalkyl dipeptidesEBI
TBA
 
Phosphinic acid inhibitors of matrix metalloproteinasesEBI
TBA
 
Rapid synthesis of novel dipeptide inhibitors of human collagenase and gelatinase using solid phase chemistryEBI
TBA
 
Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the N-carboxyalkylamine and glutaramide carboxylate seriesEBI
TBA
 
Inhibitors of MMP-1: an examination of P1′ Cα gem-disubstitution in the succinamide hydroxamate seriesEBI
TBA
 
Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2′-P3′ amide bond isostereEBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1'EBI
TBA
 
Hydroxamate inhibitors of human gelatinase B (92 kDa)EBI
TBA
 
Hydroxamate inhibitors of the matrix metallo-proteinases (MMPs) containing novel P1′ heteroatom based modificationsEBI
TBA
 
Relationship between structure and bioavailability in a series of hydroxamate based metalloprotease inhibitorsEBI
TBA
 
Synthesis of thiophenol derivatives as inhibitors of human collagenaseEBI
TBA
 
Inhibitors of human collagenase: dipeptide mimetics with lactam and azalactam moieties at the P2′/P3′ positionEBI
TBA
 
Inhibition of matrix metalloproteinases by N-carboxyalkyl dipeptides: Enhanced potency and selectivity with substituted P1′ homophenylalaninesEBI
TBA
 
Inhibition of metalloproteinase by futoenone derivativesEBI
TBA
 
Novel indolactam-based inhibitors of matrix metalloproteinasesEBI
TBA
 
Aminophosphonic acid containing inhibitors of human collagenase: modification of the P1 residueEBI
TBA
 
Synthesis and biological evaluation of a library containing potentially 1600 amides / esters. A strategy for rapid compound generation and screening.EBI
TBA
 
Potent and selective inhibitors of gelatinase-A 2. carboxylic and phosphonic acid derivativesEBI
TBA
 
Potent and selective inhibitors of gelatinase-a 1. hydroxamic acid derivativesEBI
TBA
 
Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acidsEBI
TBA
Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition.EBI
Incyte
Synthesis and activity of tryptophan sulfonamide derivatives as novel non-hydroxamate TNF-alpha converting enzyme (TACE) inhibitors.EBI
Wyeth Research
Synthesis and biological evaluation of ((4-keto)-phenoxy)methyl biphenyl-4-sulfonamides: a class of potent aggrecanase-1 inhibitors.EBI
Wyeth Research
Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.EBI
University Of California
Dual inhibitors of matrix metalloproteinases and carbonic anhydrases: iminodiacetyl-based hydroxamate-benzenesulfonamide conjugates.EBI
Instituto Superior TéCnico
Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI
Pfizer
Specific targeting of metzincin family members with small-molecule inhibitors: progress toward a multifarious challenge.EBI
University Of Athens
Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.EBI
Université
Discovery of betamethasone 17alpha-carbamates as dissociated glucocorticoid receptor modulators in the rat.EBI
Merck Research Laboratories
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors.EBI
Università
Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.EBI
Pfizer
beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 2. Optimization of alpha-amino substituents.EBI
Johnson & Johnson Pharmaceutical Research And Development
Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1' permutations.EBI
Incyte
Design and identification of selective HER-2 sheddase inhibitors via P1' manipulation and unconventional P2' perturbations to induce a molecular metamorphosis.EBI
Incyte
A novel series of highly selective inhibitors of MMP-3.EBI
Pfizer
Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.EBI
Pfizer
Simultaneous presence of unsaturation and long alkyl chain at P'1 of Ilomastat confers selectivity for gelatinase A (MMP-2) over gelatinase B (MMP-9) inhibition as shown by molecular modelling studies.EBI
Université
Hydantoins, triazolones, and imidazolones as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
A new 4-(2-methylquinolin-4-ylmethyl)phenyl P1' group for the beta-amino hydroxamic acid derived TACE inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer.EBI
Incyte
Discovery of novel hydantoins as selective non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
alpha-Biphenylsulfonylamino 2-methylpropyl phosphonates: enantioselective synthesis and selective inhibition of MMPs.EBI
Università
Identification of potent and selective TACE inhibitors via the S1 pocket.EBI
Wyeth Research
Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design and synthesis of butynyloxyphenyl beta-sulfone piperidine hydroxamates as TACE inhibitors.EBI
Wyeth Research
Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.EBI
Johnson & Johnson Pharmaceutical Research And Development
A cassette-dosing approach for improvement of oral bioavailability of dual TACE/MMP inhibitors.EBI
Novartis Institutes For Biomedical Research
Synthesis and structure-activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.EBI
Wyeth Research
Selective inhibition of matrix metalloproteinase isozymes and in vivo protection against emphysema by substituted gamma-keto carboxylic acids.EBI
Chinese Academy Of Sciences
Matrix metalloproteinase target family landscape: a chemometrical approach to ligand selectivity based on protein binding site analysis.EBI
Aventis Pharma Deutschland
Conversion of potent MMP inhibitors into selective TACE inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Receptor flexibility in de novo ligand design and docking.EBI
De Novo Pharmaceuticals
Synthesis and SAR of highly selective MMP-13 inhibitors.EBI
Wyeth Research
Acetylenic TACE inhibitors. Part 2: SAR of six-membered cyclic sulfonamide hydroxamates.EBI
Wyeth Research
Identification of potent and selective MMP-13 inhibitors.EBI
Wyeth Research
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.EBI
Pfizer
Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.EBI
Pfizer
Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.EBI
Pfizer
Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
A new development of matrix metalloproteinase inhibitors: twin hydroxamic acids as potent inhibitors of MMPs.EBI
Università
Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.EBI
Pfizer
Synthesis and SAR of diazepine and thiazepine TACE and MMP inhibitors.EBI
Wyeth Research
Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13).EBI
Pharmaceutical Research Institute
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.EBI
Wyeth Research
Synthesis and structure-activity relationship of a novel sulfone series of TNF-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and evaluation of novel oxazoline MMP inhibitors.EBI
North Dakota State University
3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.EBI
Pfizer
Benzodiazepine inhibitors of the MMPs and TACE. Part 2.EBI
Wyeth Research
Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.EBI
Hokkaido Collaboration Center N-21
Synthesis and biological activity of selective azasugar-based TACE inhibitors.EBI
Organon K.K.
Evaluation of P1'-diversified phosphinic peptides leads to the development of highly selective inhibitors of MMP-11.EBI
University Of Athens
Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.EBI
Chinese Academy Of Sciences
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 2: lead optimization.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Rational design, synthesis and structure-activity relationships of a cyclic succinate series of TNF-alpha converting enzyme inhibitors. Part 1: lead identification.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.EBI
Pfizer
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.EBI
Pfizer
Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.EBI
Wyeth Research
Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.EBI
Hokkaido Collaboration Center
Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.EBI
Hokkaido Collaboration Center
Novel inhibitors of procollagen C-proteinase. Part 2: glutamic acid hydroxamates.EBI
Combichem
Synthesis of radiolabeled biphenylsulfonamide matrix metalloproteinase inhibitors as new potential PET cancer imaging agents.EBI
Indiana University School Of Medicine
Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Organon K.K.
Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives.EBI
Université
Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.EBI
Wyeth-Ayerst Research
Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.EBI
Bristol-Myers Squibb
Benzodiazepine inhibitors of the MMPs and TACE.EBI
Wyeth Research
Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.EBI
Pfizer
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' group.EBI
Wyeth-Ayerst Research
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 1: Structure-based design of novel acetylenic P1' groups.EBI
Wyeth-Ayerst Research
Encounter with unexpected collagenase-1 selective inhibitor: switchover of inhibitor binding pocket induced by fluorine atom.EBI
Organon K.K.
New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.EBI
Organon K.K.
Design and synthesis of dual inhibitors for matrix metalloproteinase and cathepsin.EBI
Organon K.K.
Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.EBI
Abbott Laboratories
Potent P1' biphenylmethyl substituted aggrecanase inhibitors.EBI
Bristol-Myers Squibb Pharma
Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).EBI
Glaxosmithkline
Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-alpha converting enzyme.EBI
Abbott Laboratories
alpha-Amino-beta-sulphone hydroxamates as potent MMP-13 inhibitors that spare MMP-1.EBI
Pfizer
Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.EBI
Dupont Pharmaceuticals
Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.EBI
Dupont Pharmaceuticals
Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold.EBI
UniversitäT Bielefeld
Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor.EBI
British Biotech Pharmaceuticals
Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.EBI
Université
N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.EBI
Université
N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution.EBI
Glaxosmithkline
The development of new carboxylic acid-based MMP inhibitors derived from a cyclohexylglycine scaffold.EBI
Procter And Gamble Pharmaceuticals
A new concept for multidimensional selection of ligand conformations (MultiSelect) and multidimensional scoring (MultiScore) of protein-ligand binding affinities.EBI
The Royal Danish School Of Pharmacy
Discovery and characterization of the potent, selective and orally bioavailable MMP inhibitor ABT-770.EBI
Abbott Laboratories
Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.EBI
Abbott Laboratories
Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.EBI
Pfizer
Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.EBI
Roche Research Center
Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines.EBI
Procter And Gamble Pharmaceuticals
Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).EBI
Pfizer
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.EBI
Pfizer
General synthesis of alpha-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors.EBI
Institut De Recherches Servier
Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines.EBI
Procter And Gamble Pharmaceuticals
Solid-phase synthesis of an arylsulfone hydroxamate library.EBI
Rhone-Poulenc Rorer
Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.EBI
Pfizer
Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties.EBI
Università
Design and synthesis of piperazine-based matrix metalloproteinase inhibitors.EBI
Procter And Gamble Pharmaceuticals
Design, synthesis, and biological evaluation of matrix metalloproteinase inhibitors derived from a modified proline scaffold.EBI
University Of Florida
New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors.EBI
Astrazeneca
Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.EBI
Smithkline Beecham Pharmaceuticals
The synthesis and biological evaluation of non-peptidic matrix metalloproteinase inhibitors.EBI
British Biotech Pharmaceuticals
Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study.EBI
Cea
Synthesis and identification of conformationally constrained selective MMP inhibitors.EBI
Searle Discovery Research
P1, P2'-linked macrocyclic amine derivatives as matrix metalloproteinase inhibitors.EBI
Dupont Pharmaceuticals
Discovery of a novel series of selective MMP inhibitors: identification of the gamma-sulfone-thiols.EBI
Searle Discovery Research
Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors.EBI
Pharmacia And Upjohn
Identification of highly selective inhibitors of collagenase-1 from combinatorial libraries of diketopiperazines.EBI
Affymax Research Institute
Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.EBI
RhôNe-Poulenc Rorer
Design and synthesis of thiol containing inhibitors of matrix metalloproteinases.EBI
Novartis Biomedical Research Institute
Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.EBI
Pfizer
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.EBI
Abbott Laboratories
The design, synthesis, and structure-activity relationships of a series of macrocyclic MMP inhibitors.EBI
Abbott Laboratories
Design and synthesis of conformationally-constrained MMP inhibitors.EBI
Procter And Gamble Pharmaceuticals
Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution.EBI
Abbott Laboratories
The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases.EBI
Wyeth-Ayerst Research
Malonyl alpha-mercaptoketones and alpha-mercaptoalcohols, a new class of matrix metalloproteinase inhibitors.EBI
Affymax Research Institute
Selective inhibition of low affinity IgE receptor (CD23) processing.EBI
Smithkline Beecham Pharmaceuticals
Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing.EBI
Smithkline Beecham Pharmaceuticals
Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.EBI
Dupont Pharmaceuticals
Rational design and combinatorial evaluation of enzyme inhibitor scaffolds: identification of novel inhibitors of matrix metalloproteinases.EBI
Affymax Research Institute
Macrocyclic amino carboxylates as selective MMP-8 inhibitors.EBI
Dupont Pharmaceuticals
Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.EBI
Dupont Pharmaceuticals
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.EBI
Kanebo
Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.EBI
Shionogi
Dual inhibition of human leukocyte elastase and lipid peroxidation: in vitro and in vivo activities of azabicyclo[2.2.2]octane and perhydroindole derivatives.EBI
Institut De Recherche Servier
Synthesis of novel N-phosphonoalkyl dipeptide inhibitors of human collagenase.EBI
Smithkline Beecham Pharmaceuticals
Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides.EBI
Merck Research Laboratories
Synthesis of novel modified dipeptide inhibitors of human collagenase: beta-mercapto carboxylic acid derivatives.EBI
Smithkline Beecham Pharmaceuticals
Matrix metalloproteinase inhibitors containing a (carboxyalkyl)amino zinc ligand: modification of the P1 and P2' residues.EBI
Glaxo Inc. Research Institute
Inhibition of matrix metalloproteinases by hydroxamates containing heteroatom-based modifications of the P1' group.EBI
Sterling Winthrop Pharmaceuticals Research Division
Three new aromatic sulfonamide inhibitors of carbonic anhydrases I, II, IV and XII.BDB
Universit?? Di Firenze
Design, synthesis and pharmacological evaluation of conformationally restricted N-arylsulfonyl-3-aminoalkoxy indoles as a potential 5-HT6 receptor ligands.BDB
Suven Life Sciences
DL-threo-beta-benzyloxyaspartate, a potent blocker of excitatory amino acid transporters.BDB
Suntory Institute For Bioorganic Research
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.BDB
Eli Lilly
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.BDB
National Institute Of Neurological Disorders And Stroke
Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.BDB
Vernalis (R&D
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction based on an isoindolinone scaffold.BDB
University Of Newcastle Upon Tyne
Synthesis and PKCtheta inhibitory activity of a series of 4-indolylamino-5-phenyl-3-pyridinecarbonitriles.BDB
Wyeth Research
Novel tricyclic inhibitors of IkappaB kinase.BDB
Bristol-Myers Squibb